806 related articles for article (PubMed ID: 28270211)
1. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.
Ibrahim SA; Hassan H; Vilardo L; Kumar SK; Kumar AV; Kelsch R; Schneider C; Kiesel L; Eich HT; Zucchi I; Reinbold R; Greve B; Götte M
PLoS One; 2013; 8(12):e85737. PubMed ID: 24392029
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
4. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
5. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
[TBL] [Abstract][Full Text] [Related]
6. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
8. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways.
Lin C; Wang L; Wang H; Yang L; Guo H; Wang X
J Cell Biochem; 2013 Sep; 114(9):2061-70. PubMed ID: 23553622
[TBL] [Abstract][Full Text] [Related]
10. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.
Hsu EC; Kulp SK; Huang HL; Tu HJ; Salunke SB; Sullivan NJ; Sun D; Wicha MS; Shapiro CL; Chen CS
Neoplasia; 2015 Jun; 17(6):497-508. PubMed ID: 26152358
[TBL] [Abstract][Full Text] [Related]
11. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
12. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.
Lacerda L; Debeb BG; Smith D; Larson R; Solley T; Xu W; Krishnamurthy S; Gong Y; Levy LB; Buchholz T; Ueno NT; Klopp A; Woodward WA
Breast Cancer Res; 2015 Mar; 17(1):42. PubMed ID: 25887413
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
[TBL] [Abstract][Full Text] [Related]
15. Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas.
El-Nadi M; Hassan H; Saleh ME; Nassar E; Ismail YM; Amer M; Greve B; Götte M; El-Shinawi M; Ibrahim SA
Matrix Biol Plus; 2020 May; 6-7():100030. PubMed ID: 33543027
[TBL] [Abstract][Full Text] [Related]
16. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.
Chung SS; Vadgama JV
Anticancer Res; 2015 Jan; 35(1):39-46. PubMed ID: 25550533
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
18. TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways.
Liu M; Inoue K; Leng T; Guo S; Xiong ZG
Cell Signal; 2014 Dec; 26(12):2773-81. PubMed ID: 25192910
[TBL] [Abstract][Full Text] [Related]
19. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.
Aoki S; Mizuma M; Takahashi Y; Haji Y; Okada R; Abe T; Karasawa H; Tamai K; Okada T; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Katayose Y; Unno M
BMC Cancer; 2016 Nov; 16(1):854. PubMed ID: 27821106
[TBL] [Abstract][Full Text] [Related]
20. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]